This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages without signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

vitamin D sufficiency and survival and cardiovascular outcomes in breast cancer

Authoring team

Vitamin D sufficiency and survival and cardiovascular outcomes in breast cancer

  • a large prospective cohort study (Pathways Study and Pathways Heart Study) evaluated the association between serum 25-hydroxyvitamin D (25OHD) concentrations near diagnosis and long-term cancer survival and cardiovascular outcomes in 3,995 women with incident invasive breast cancer
  • study design and baseline vitamin D status:
    • serum 25OHD was measured at a median of 69 days after breast cancer diagnosis and categorised using clinical cut points: deficient (<20.0 ng/mL [50 nmol/L]; 38% of cohort), insufficient (20.0–29.9 ng/mL [50–74.9 nmol/L]; 37%), and sufficient ( 30.0 ng/mL [75 nmol/L]; 25%)
    • median follow-up was 12.2 years (range 0.2 to 16.3 years), with primary time-to-event models capped at 12 years and adjusted for demographic, lifestyle, clinical, tumour, and treatment variables
    • lower 25OHD levels were significantly associated with higher BMI, non-Hispanic Black and Hispanic race/ethnicity, younger age (<50 years), physical inactivity, smoking, lack of vitamin D supplementation, and more aggressive tumour characteristics (higher stage, poor differentiation, oestrogen receptor-negative, and triple-negative subtypes)

Cancer survival outcomes

  • compared with vitamin D deficiency (<20.0 ng/mL), clinically sufficient vitamin D levels ( 30.0 ng/mL) were associated with significantly improved survival outcomes:
    • overall survival (OS): adjusted hazard ratio (HR) 0.76 (95% CI 0.62 to 0.93; for trend = 0.005)
    • second primary cancer-free survival: HR 0.75 (95% CI 0.63 to 0.90; for trend = 0.003)
    • disease-free survival (DFS): HR 0.82 (95% CI 0.70 to 0.97; for trend = 0.05)
  • non-significant survival endpoints: breast cancer-specific survival (HR 0.87, 95% CI 0.64 to 1.17; for trend = 0.78) and recurrence-free survival (HR 0.85, 95% CI 0.70 to 1.02; for trend = 0.07) showed favourable point estimates without reaching statistical significance in fully adjusted models
  • stage interaction: stratified analyses indicated stronger survival associations among patients with stage II or more advanced disease ( for interaction 0.02), independent of tumour oestrogen receptor status, BMI, comorbidities, or post-diagnosis calcium supplement use

Cardiometabolic and cardiovascular outcomes

  • cardiometabolic risk factors: vitamin D sufficiency versus deficiency was associated with significantly lower risks of developing new cardiometabolic conditions (accounting for all-cause death as a competing risk):
    • any incident cardiometabolic risk factor: subdistribution HR (sHR) 0.67 (95% CI 0.54 to 0.83; for trend < 0.001)
    • incident diabetes mellitus: sHR 0.69 (95% CI 0.50 to 0.94; for trend = 0.009)
    • incident dyslipidaemia: sHR 0.71 (95% CI 0.56 to 0.90; for trend = 0.006)
    • incident hypertension: no statistically significant difference (sHR 0.88, 95% CI 0.69 to 1.14; for trend = 0.36)
  • cardiovascular disease (CVD) events and mortality:
    • sufficient vitamin D levels showed non-significant trends toward lower hazards of any incident CVD event (sHR 0.82, 95% CI 0.66 to 1.02; for trend = 0.06) and venous thromboembolism (sHR 0.67, 95% CI 0.44 to 1.03; for trend = 0.07)
    • importantly, higher vitamin D levels were not associated with increased CVD-related death (sHR 0.74, 95% CI 0.47 to 1.15; for trend = 0.19) or stroke (sHR 1.04, 95% CI 0.62 to 1.72; for trend = 0.88)

Limitations and clinical implications

  • study limitations: reliance on a single baseline serum 25OHD measurement near diagnosis (with survival curves converging after approximately 12 years), observational design with potential residual confounding, and absence of ECOG performance status data
  • clinical practice considerations:
    • because women treated for invasive breast cancer face elevated cardiometabolic and cardiovascular risks alongside cancer recurrence risk, routine screening for vitamin D deficiency after breast cancer diagnosis may be advisable
    • where deficiency or insufficiency is identified, correction with moderate daily vitamin D supplementation (below the upper tolerable limit of 4,000 IU daily, avoiding high-dose intermittent bolus regimens) supports bone health and is associated with improved overall survival and cardiometabolic profiles without increasing cardiovascular mortality

Reference:

  1. Yao S, Chua AV Jr, Sheng H, et al. Clinically Sufficient Vitamin D Levels With Survival and Cardiovascular Outcomes in a Prospective Cohort of 3,995 Individuals Diagnosed With Invasive Breast Cancer. J Natl Compr Canc Netw. 2026;24(4):e257111.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.